A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

NCT01205737 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

DLBCL

Interventions

BIOLOGICAL: TL011
BIOLOGICAL: Rituximab

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.